Phase I Clinical Investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942)

Daniel D. Von Hoff, J. William Myers, John Kuhn, John F. Sandbach, Robert Pocelinko, Gary Clark, Charles A. Coltman

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

9,10-Anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imi-dazol-2-yl)hydrazone] dihydrochloride (CL216,942) is a new anthracene bishydrazone derivative that was evaluated in a Phase I clinical trial. The schedule of administration consisted of a single i.v. injection repeated at 4-week intervals. Twenty-eight patients received a total of 61 courses of the drug in a dose range of 20 to 280 mg/sq m. Leukopenia was the dose-limiting toxicity. It was of short duration and reversible. A drug-induced hypotension was noted at higher doses in three patients. The hypotension was not dose limiting, it was reversible, and it could largely be avoided by prolonging the drug infusion time to 1 hr. One patient with unsuspected severe coronary artery disease died of complications of myocardial infarction subsequent to a hypotensive episode. Significant phlebitis was also noted at higher doses of drug. This degree of phlebitis could be lessened by diluting the drug in larger volumes of fluid. Three patients experienced diaphoresis, nausea, palpitations, and chest discomfort at the conclusion of the infusions. None of the patients had electrocardiographic changes. Mild fever, alopecia, and nausea and vomiting were noted occasionally. One patient with a hypernephroma and one patient with hepatocellular carcinoma experienced partial responses of their tumors secondary to the drug. Phase ll studies of CL216,942 are planned at a starting dose of 260 mg/sq m as a single dose repeated at 21- to 28-day intervals.

Original languageEnglish (US)
Pages (from-to)3118-3121
Number of pages4
JournalCancer Research
Volume41
Issue number8
StatePublished - Aug 1 1981
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase I Clinical Investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942)'. Together they form a unique fingerprint.

Cite this